Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (ASSURE)

This study has been completed.
Cancer and Leukemia Group B
NCIC Clinical Trials Group
Southwest Oncology Group
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: May 16, 2006
Last updated: July 18, 2016
Last verified: July 2016